<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by BCnewswire on Medium]]></title>
        <description><![CDATA[Stories by BCnewswire on Medium]]></description>
        <link>https://medium.com/@bcnewswire?source=rss-5b2789a49ff6------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/1*fq2zu-RdtU23_eMgdB3MzA.jpeg</url>
            <title>Stories by BCnewswire on Medium</title>
            <link>https://medium.com/@bcnewswire?source=rss-5b2789a49ff6------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Sat, 21 Nov 2026 02:46:45 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@bcnewswire/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[Magnetic Nanoparticles Deliver Targeting, Real-Time Tracking for Breast Cancer Patients]]></title>
            <link>https://medium.com/@bcnewswire/magnetic-nanoparticles-deliver-targeting-real-time-tracking-for-breast-cancer-patients-301059682f55?source=rss-5b2789a49ff6------2</link>
            <guid isPermaLink="false">https://medium.com/p/301059682f55</guid>
            <category><![CDATA[breast-cancer]]></category>
            <category><![CDATA[nanotechnology]]></category>
            <category><![CDATA[nanoparticles]]></category>
            <dc:creator><![CDATA[BCnewswire]]></dc:creator>
            <pubDate>Wed, 07 Feb 2024 14:15:21 GMT</pubDate>
            <atom:updated>2024-02-07T14:15:21.174Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*qKcWnyie3kvRzURLHY5b9g.png" /></figure><p>Traditional cancer treatments, including those for breast cancer, often struggle because the drugs used can’t specifically target tumor cells without also affecting healthy ones.</p><p>This lack of specificity leads to reduced effectiveness and harmful side effects. Additionally, it’s hard for doctors to monitor how well the treatment is working in real-time, making it difficult to adjust dosages and strategies for the best outcomes.</p><p>Researchers in China have <a href="https://pubs.rsc.org/en/content/articlelanding/2024/na/d3na00814b">developed</a> an advanced treatment system that combines therapy and imaging in one package, using tiny particles called nanoparticles. These nanoparticles are designed to carry drugs directly to cancer cells, making treatment more effective while minimizing side effects. They can also be tracked inside the body, allowing doctors to see how well the treatment is working.</p><p>The team created nanoparticles that can carry a photothermal agent (IR780), a drug that’s attracted to cancer cells (OA@Fe3O4), and a common cancer drug (paclitaxel). These nanoparticles are guided by magnets to accumulate at the tumor site, where they release the drugs and create heat when exposed to a specific type of light. This heat helps the drugs work better and allows doctors to track the treatment’s progress through imaging.</p><p>These nanoparticles showed promising results in both lab dishes and live animal models. They were able to effectively target tumor cells, release their drug payload in a controlled manner, and significantly reduce tumor size. Importantly, the ability to track these nanoparticles in the body in real-time could help doctors make more informed decisions about treatment adjustments.</p><p>The nanoparticles were made by mixing specific quantities of the photothermal agent, cancer drugs, and a material that helps the particles form (PEG-PCL) in a solvent. This mixture was then processed to remove the solvent, leaving behind the nanoparticles loaded with the treatment agents.</p><p>Tests showed that these nanoparticles could successfully reach and penetrate tumor cells, release their drug content when exposed to light, and generate heat for photothermal therapy. They were more effective at killing cancer cells compared to traditional treatment methods and were able to significantly inhibit tumor growth in mice models.</p><p>This study represents a significant step forward in cancer treatment, offering a more targeted, effective, and trackable method of delivering drugs to tumors. The nanoparticles’ ability to combine therapy with real-time imaging could revolutionize how breast cancer is treated, providing a tailored approach that maximizes effectiveness while minimizing harm to healthy cells.</p><p>Although these findings are promising, further research is needed to fully understand the potential and safety of these nanoparticles in humans. If successful, this technology could lead to more personalized and effective treatments for breast cancer and potentially other types of cancer as well.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=301059682f55" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Heart Health on HER2 Therapy: What Every Breast Cancer Patient Needs to Know]]></title>
            <link>https://medium.com/@bcnewswire/heart-health-on-her2-therapy-what-every-breast-cancer-patient-needs-to-know-029e63ce283f?source=rss-5b2789a49ff6------2</link>
            <guid isPermaLink="false">https://medium.com/p/029e63ce283f</guid>
            <category><![CDATA[hormone-therapy]]></category>
            <category><![CDATA[her2]]></category>
            <category><![CDATA[ekg-technician]]></category>
            <category><![CDATA[breast-cancer]]></category>
            <dc:creator><![CDATA[BCnewswire]]></dc:creator>
            <pubDate>Wed, 07 Feb 2024 13:54:17 GMT</pubDate>
            <atom:updated>2024-02-07T13:54:17.382Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*QC3o_lwevz44oRTFR7-C8Q.png" /></figure><p>If you’re a breast cancer patient undergoing treatment with HER2-targeted therapies, it’s essential to keep an eye on your heart health.</p><p>These powerful treatments can sometimes affect the heart, so monitoring your heart function through regular check-ups can help catch any issues early.</p><p>A new <a href="https://physicianresources.dana-farber.org/flexpaper/treatment-guidelines-tailored-echocardiographic-monitoring-in-breast-cancer-patients-receiving-her2-directed-treatments-and/or-anthracyclines">guide</a> from the Dana-Farber Breast Oncology Center presents a consensus statement on tailored echocardiographic monitoring for patients with early or advanced breast cancer who are receiving HER2-directed treatments or anthracyclines.</p><p>It outlines the risk of cardiotoxicity associated with these treatments and provides detailed clinical recommendations for baseline and on-treatment echocardiographic monitoring to manage and mitigate these risks.</p><p>The consensus emphasizes a risk-adapted approach to echocardiography, recommending monitoring intervals based on individual patient risk factors for cardiotoxicity.</p><p>Additionally, it discusses the use of dexrazoxane and liposomal doxorubicin as strategies to reduce cardiotoxicity, highlighting the importance of early detection and management of cardiac side effects in patients undergoing these cancer treatments.</p><p>Heart monitoring through echocardiography is considered important for breast cancer patients receiving HER2-directed therapies or anthracyclines because these treatments can lead to cardiotoxicity, which is damage to the heart muscle. This damage can result in heart failure or other serious heart conditions.</p><p>The risk is higher in patients with pre-existing heart conditions, older age, or those receiving higher doses of these drugs. Monitoring is crucial to detect and manage heart issues early, allowing for adjustments in cancer treatment or the introduction of heart-protective measures to minimize long-term heart damage.</p><p>By monitoring the heart’s function before and during treatment, doctors can identify early signs of heart damage, allowing for timely intervention. This can include adjusting cancer treatment or adding heart-protective medications to prevent further damage, ultimately improving the patient’s overall health and treatment outcome.</p><p>By working closely with your healthcare team to track your heart’s health, you can ensure your cancer treatment is as safe and effective as possible, keeping you on the path to recovery while protecting your heart.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=029e63ce283f" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Portable AI Tool Uses Body Heat to Spot Breast Cancer in Minutes]]></title>
            <link>https://medium.com/@bcnewswire/portable-ai-tool-uses-body-heat-to-spot-breast-cancer-in-minutes-42cecc149a43?source=rss-5b2789a49ff6------2</link>
            <guid isPermaLink="false">https://medium.com/p/42cecc149a43</guid>
            <category><![CDATA[screening]]></category>
            <category><![CDATA[breast-cancer]]></category>
            <category><![CDATA[imaging-technology]]></category>
            <category><![CDATA[imaging]]></category>
            <category><![CDATA[medical]]></category>
            <dc:creator><![CDATA[BCnewswire]]></dc:creator>
            <pubDate>Wed, 07 Feb 2024 12:53:31 GMT</pubDate>
            <atom:updated>2024-02-07T12:53:31.482Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*Ob4knYfsIf6OZl30B6x9MA.png" /></figure><p>Researchers from Nanyang Technological University in Singapore have created a new computer program that can spot potential breast tumors by analyzing the heat they emit, which is different from that of healthy breast tissue.</p><p>This program, called Physics-informed Neural Network (PINN), uses artificial intelligence and thermal imaging to quickly identify signs of malignant tumors in breast scans.</p><p>It was developed with the help of doctors and researchers from Kazakhstan and Singapore and has shown a 91% accuracy rate in tests.</p><p>The PINN system works by taking infrared images of the breast and looking for unusual heat patterns, which can be done in about five minutes. This method is non-invasive, does not require heavy equipment, and poses no radiation risk, making it a safer option for those at higher risk of breast cancer. However, it’s meant to complement, not replace, traditional diagnostic methods like mammograms.</p><p>The development of PINN is part of a broader effort to improve early detection of breast cancer, especially in areas where access to traditional mammography is limited.</p><p>This approach could make breast cancer screening more accessible and efficient, helping to prioritize care for those with the most severe cases.</p><p>The team is working to enhance PINN further so it can be used on portable devices for easy use in routine checks, with the hope of making early detection simpler and more widespread.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=42cecc149a43" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[The Promising Fight Against Breast Cancer with B7-H3]]></title>
            <link>https://medium.com/@bcnewswire/the-promising-fight-against-breast-cancer-with-b7-h3-a1642f4713c8?source=rss-5b2789a49ff6------2</link>
            <guid isPermaLink="false">https://medium.com/p/a1642f4713c8</guid>
            <category><![CDATA[drug-discovery]]></category>
            <category><![CDATA[breast-cancer]]></category>
            <category><![CDATA[breast-cancer-treatment]]></category>
            <category><![CDATA[drug-discovery-chemistry]]></category>
            <dc:creator><![CDATA[BCnewswire]]></dc:creator>
            <pubDate>Wed, 07 Feb 2024 12:47:06 GMT</pubDate>
            <atom:updated>2024-02-07T12:47:06.479Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*M7zDGUv1kLG1RT3a8iOt-w.png" /></figure><p>Breast cancer is a major cause of death for women around the world, largely due to a mix of genetic and environmental factors.</p><p>Traditional treatments have limitations, leading to intense research to find better solutions.</p><p>One promising area of research is targeting the immune system’s response to tumors, particularly through a protein called B7-H3, which has shown to play a significant role in the progression and resistance of breast cancer to treatments.</p><p>High levels of B7-H3 in breast cancer are linked to the cancer’s ability to evade the immune system and become more aggressive and resistant to drugs. This has made B7-H3 an attractive target for new immunotherapies.</p><p>A recent study from Nanjing Medical University closely <a href="https://bmccancer.biomedcentral.com/articles/10.1186/s12885-024-11933-3">examined</a> B7-H3’s structure, how it regulates the immune response, and its dual role in stimulating and inhibiting T cells, which are a type of immune cell. It also explored how B7-H3 contributes to the aggressive behavior of breast cancer, including its growth, spread to other parts of the body, and resistance to treatments.</p><p>Of particular interest, the study highlighted the ongoing research into drugs that target B7-H3, offering new hope for treating breast cancer.</p><p>Breast cancer is divided into different types based on certain receptors found on cancer cells, which can influence treatment options.</p><p>Despite advances in treatment, many patients still face a poor prognosis, especially those with triple-negative breast cancer, which lacks specific receptors and is harder to treat. The complex environment of breast tumors, involving various types of cells, also affects the disease’s progression and response to treatment.</p><p>Therefore, understanding and targeting the role of proteins like B7-H3 in the immune response to cancer is critical for developing more effective therapies.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=a1642f4713c8" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Suspected Breast Cancer Cluster at NC State: PCB in Crosshairs]]></title>
            <link>https://medium.com/@bcnewswire/suspected-breast-cancer-cluster-at-nc-state-pcb-in-crosshairs-a616b3515e16?source=rss-5b2789a49ff6------2</link>
            <guid isPermaLink="false">https://medium.com/p/a616b3515e16</guid>
            <category><![CDATA[breast-cancer]]></category>
            <dc:creator><![CDATA[BCnewswire]]></dc:creator>
            <pubDate>Tue, 06 Feb 2024 21:02:57 GMT</pubDate>
            <atom:updated>2024-02-06T21:02:57.299Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*oxqVDH9MgQ06rqEr0F6KYQ.png" /></figure><p>The results of a <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7387141/">study</a> that have just been released highlights concerns over a suspected breast cancer cluster at NC State University’s Poe Hall, attributed to high levels of PCBs (polychlorinated biphenyls), a likely carcinogen found in the building.</p><p>Testing revealed significant PCB contamination in five rooms and air systems of Poe Hall, prompting the university to shut down the affected areas and relocate activities.</p><p>The university sought a Health Hazard Evaluation from the CDC concerning the potential cancer cluster, but progress on this evaluation was halted last month at NC State’s request, as reported by WRAL, citing the CDC. The university has engaged legal and environmental health experts to address the contamination issue.</p><p>PCBs, extensively manufactured by Monsanto and used in various applications until their ban in 1979, are known for their environmental persistence and potential health risks, including cancer and damage to multiple body systems.</p><p>A 2020 study involving nearly 800 North Carolina women linked high levels of certain PCBs to increased breast cancer mortality, underscoring the severity of the concerns at Poe Hall. This study found that women with higher blood levels of specific PCBs had a greater risk of dying from breast cancer, with particular types of PCBs associated with higher mortality rates.</p><p>The situation at Poe Hall and the associated health risks from PCB exposure, especially in relation to breast cancer, underline the ongoing challenges of managing legacy contaminants in older buildings and the critical need for comprehensive health and environmental safety assessments.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=a616b3515e16" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[FDA Fast-Tracks Promising New Breast Cancer Drug for Advanced Cases]]></title>
            <link>https://medium.com/@bcnewswire/fda-fast-tracks-promising-new-breast-cancer-drug-for-advanced-cases-42b19fb7b483?source=rss-5b2789a49ff6------2</link>
            <guid isPermaLink="false">https://medium.com/p/42b19fb7b483</guid>
            <category><![CDATA[breast-cancer]]></category>
            <category><![CDATA[breast-cancer-treatment]]></category>
            <dc:creator><![CDATA[BCnewswire]]></dc:creator>
            <pubDate>Tue, 06 Feb 2024 21:01:03 GMT</pubDate>
            <atom:updated>2024-02-06T21:01:03.157Z</atom:updated>
            <content:encoded><![CDATA[<p>FDA Fast-Tracks Promising New Breast Cancer Drug for Advanced Cases</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*oKRtbAbbSMkJfbSS4EpEyw.png" /></figure><p>The FDA has given a special fast track status to a new breast cancer medication called <a href="https://ir.arvinas.com/news-releases/news-release-details/arvinas-and-pfizers-vepdegestrant-arv-471-receives-fda-fast">vepdegestran</a>t (ARV-471) for adults with a certain type of breast cancer (ER-positive/HER2-negative) that has spread and who have already tried hormone-based treatments. This medication is taken by mouth and works by breaking down a protein that helps cancer cells grow. Early studies show it can significantly shrink tumors in lab models.</p><p>This fast track status means the FDA recognizes the drug’s potential to meet an urgent medical need, speeding up its review process. The developers, Arvinas, Inc., are excited about this step and are committed to quickly advancing the treatment’s development for patients who need new options.</p><p>In a detailed study (VERITAC study), the drug was tested with another medication, palbociclib, in patients who had received a lot of previous treatments. They found the combination to be effective, with many patients seeing their cancer stop growing or shrink, especially those with a certain mutation in their cancer cells. The combination also showed a manageable level of side effects, like low white blood cell counts and fatigue, but was generally well-tolerated.</p><p>Further studies are ongoing to compare vepdegestrant to other treatments and to explore its use as an initial treatment option, showing the promise of this new approach in managing advanced breast cancer.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=42b19fb7b483" width="1" height="1" alt="">]]></content:encoded>
        </item>
    </channel>
</rss>